Biosimilars Congregation 2012

Top Quote "Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars" February 24th 2012, Hilton London Euston Hotel, London UK. End Quote
  • (1888PressRelease) December 21, 2011 - Key Themes Discussed at this Summit:

    Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease
    How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
    How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
    Identifying issues and solutions surrounding biosimiliars and clinical trials.
    Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
    Overcoming pricing and reimbursement challenges to maximise the ROI
    Determining the right investments & potential returns from Biosimilars
    Commercial challenges and opportunities - strategies to develop Biosimilars
    Biosimilars Vs Bio-betters - positioning for a new market with lucrative prospects
    Learn to implement best practices through recent successful strategies and business models - real time case studies
    Analyze the FDA's current view of biosimilars
    The developing regulatory framework in advanced and developing markets
    EMA Regulatory Opinions on Treatment of mAbs
    Critical issues in demonstrating biosimilarity and maintaining diligent quality control
    Be part of a major networking opportunity

    Who Should Attend:

    CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:


    Analytics
    Business Development
    Business Strategy
    Corporate Development Strategy
    Commercial Affairs
    Intellectual Property
    Marketing & Sales
    Medical Affairs
    NewProduct Development
    Legal Affairs
    CMC
    Preclinical and Clinical Development
    Product Development
    Regulatory Affairs
    Pricing and Reimbursement
    Research and Development
    Biologic Production
    Quality Assurance
    Scientific Affairs
    Strategic Planning
    Strategic Sourcing

    Key Speakers Include:

    Claudio Carini, Translational Medicine, Pfizer
    Deven Parmar, Vice President - Global Clinical Research, Wockhardt (India)
    Paul Greenland, Biosimilars and Proprietary Marketing Director - EMEA, Hospira, UK
    Keith Powell, Chairman, Domainex (Former CEO, Polytherics)
    Cecil Nick, Vice President - Biotechnology, Parexel
    Richard Dennett, Director, Voisin Consulting Life Sciences
    Lincoln Tsang, Partner, Arnold & Porter LLP
    Kristie C. Kuhl, Senior Vice President, Makovsky + Company (USA)
    Violeta Stanimirovic, Expert of medicines and medical devices agency, Serbia-Alims & expert of Montenegrian National Drug Agency - CALIMS
    Francis P. Crawley, Executive Director, Good Clinical Practice Alliance - Europe (GCPA)
    Anthony Grosso, Associate Professor in Clinical Pharmacy Practice (Honorary), UCL Hospitals NHS Trust, University of London
    Jan Petracek, MD MSc DIC CEO, Pharminvent
    Anna Harrington Morozova, Scientific & Regulatory Director, REGEM Consulting
    Steinar Madsen, Medical Director, Norwegian Medicines Agency
    Duncan Emerton, Prinicpal Consultant, Datamonitor
    plus many more.........

    Why Should You Attend:

    Biosimilars Congregation 2012 - "Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

    Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

    Ordering Delegate Place -
    Register now as delegate, sponsor and exhibitor

    Early Bird Discounted Price - Conference Delegate Pass ( 400 + VAT per delegate) - Book and Pay before 20th December 2011 to avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.
    Email - tania @ virtue insight . com

    Standard Price after 20th December 2011 - Conference Delegate Pass ( 500 + VAT per delegate) - You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444..
    Email - tania @ virtue insight . com

    Group Discounts - 2 or 3 Delegates - 350 + VAT per delegate

    Group Discounts - 4 and above Delegates - 300 + VAT per delegate

    Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to - TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.
    Email - tania @ virtue insight . Com

    For more info on the event and for event brochure kindly visit -
    h t t p : / / w w w . virtue insight . com / pharma / Biosimilars - Congregation - 2012 /

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information